T0	Limitation 15905 15906	A
T1	Limitation 16075 16082	Because
T2	Limitation 16271 16278	Delayed
T3	Limitation 16431 16434	For
T4	Limitation 16595 16607	Furthermore,
T5	Limitation 16681 16683	We
T6	Limitation 16812 16814	We
T7	Limitation 17068 17070	An
T8	Limitation 17235 17237	We
T9	Limitation 18071 18073	In
T10	MissingData 15939 16073	we collected key baseline and outcome data, but did not call patients back for study visits for detailed assessment of quality of life
T12	MissingData 16608 16679	we do not have complete information about adherence to study medication
T13	OutcomeMeasures 16452 16553	we did not include other baseline measurements such as amount of blood in CT scan or systemic illness
T14	PrecisionOfMeasurement 16555 16593	nor did we do close on-site monitoring
T15	StudyTeam 16830 16875	the possibility of unmasking of investigators
T16	ResponsivenessOfMeasurement 17068 17233	An effect of magnesium treatment on cognitive symptoms—which are common after aneurysmal subarachnoid haemorrhage—might have been missed by the modified Rankin Scale
T17	FollowUpDuration 17371 17404	a benefit might be detected later
T18	Intervention 18088 18200	time to treatment with magnesium in MASH 2 might not have been short enough to ameliorate acute ischaemic injury
T19	OutcomeMeasures 16359 16429	we did not include delayed cerebral haemorrhage as a secondary outcome
T11	MissingData 16681 16747	We did not require magnesium concentration to be routinely checked
